| Identification | Back Directory | [Name]
(S)-ROSCOVITINE | [CAS]
186692-45-5 | [Synonyms]
Roscovitine, (S)-Isomer - CAS 186692-45-5 - Calbiochem
(2S)-2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol
1-Butanol, 2-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-, (2S)- | [Molecular Formula]
C19H26N6O | [MDL Number]
MFCD02266402 | [MOL File]
186692-45-5.mol | [Molecular Weight]
354.45 |
| Hazard Information | Back Directory | [Uses]
(S)-Roscovitine ((S)-Seliciclib; (S)-CYC202) is a potent and cross the blood-brain barrier CDKs inhibitor. (S)-Roscovitine shows neuroprotective efficacy. (S)-Roscovitine has the potential for the research of stroke[1][2]. | [in vivo]
(S)-Roscovitine (25 mg/kg; i.p.; 15 min before and 1 hr after pMCAo) shows neuroprotective efficacy in an adult mouse model of permanent MCAo (middle cerebral artery occlusion) [2]. | Animal Model: | 20-25 g, P60 male C57 b/6 mice[2] | | Dosage: | 25 mg/kg | | Administration: | I.p.; at 15 min before and 1 hr after pMCAo | | Result: | Decreased of the total infarct volume. |
| [IC 50]
CDK1: ≤1 μM (IC50); CDK2: ≤1 μM (IC50); CDK5: ≤1 μM (IC50); CDK7: ≤1 μM (IC50); CDK9: ≤1 μM (IC50) | [storage]
+4°C | [References]
[1] Le Roy L, et al. Cellular and Molecular Mechanisms of R/S-Roscovitine and CDKs Related Inhibition under Both Focal and Global Cerebral Ischemia: A Focus on Neurovascular Unit and Immune Cells. Cells. 2021 Jan 8;10(1):104. DOI:10.3390/cells10010104
[2] Menn B, et al. Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models. PLoS One. 2010 Aug 12;5(8):e12117. DOI:10.1371/journal.pone.0012117 |
|
| Company Name: |
Enzo Biochem Inc
|
| Tel: |
Enzo Biochem Inc. 13797054060 |
| Website: |
www.enzo.com |
| Company Name: |
Tinib-Tools
|
| Tel: |
+420 (606) 323-943 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15667/0_EN.htm |
|